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Abstract
Background: It remains unclear whether estrogenic botanical supplement (EBS) use influences breast cancer
survivors’ health-related outcomes.
Methods: We examined the associations of EBS use with health-related quality of life (HRQOL), with fatigue, and
with 15 hormone-related symptoms such as hot flashes and night sweats among 767 breast cancer survivors
participating in the Health, Eating, Activity, and Lifestyle (HEAL) Study. HRQOL was measured by the Medical
Outcomes Study short form-36 physical and mental component scale summary score. Fatigue was measured by
the Revised-Piper Fatigue Scale score.
Results: Neither overall EBS use nor the number of EBS types used was associated with HRQOL, fatigue, or
hormone-related symptoms. However, comparisons of those using each specific type of EBS with non-EBS users
revealed the following associations. Soy supplements users were more likely to have a better physical health
summary score (odds ratio [OR] = 1.66, 95% confidence interval [CI] = 1.02-2.70). Flaxseed oil users were more likely
to have a better mental health summary score (OR = 1.76, 95% CI = 1.05-2.94). Ginseng users were more likely to
report severe fatigue and several hormone-related symptoms (all ORs ≥ 1.7 and all 95% CIs exclude 1). Red clover
users were less likely to report weight gain, night sweats, and difficulty concentrating (all OR approximately 0.4 and
all 95% CIs exclude 1). Alfalfa users were less likely to experience sleep interruption (OR = 0.28, 95% CI = 0.12-0.68).
Dehydroepiandrosterone users were less likely to have hot flashes (OR = 0.33, 95% CI = 0.14-0.82).
Conclusions: Our findings indicate that several specific types of EBS might have important influences on a
woman’s various aspects of quality of life, but further verification is necessary.
Background
Breast cancer survivors frequently use complementary/
alternative medicines (CAM) such as estrogenic botani-
cal supplements (EBS) in hopes of improving their
health-related quality of life (HRQOL), boosting their
sense of well-being, and alleviating the side-effects of
conventional therapies [1,2]. However, no published
data exist regarding the associations of EBS use with
HRQOL, fatigue, or symptoms often characterized by a
deficit of estrogen.
Botanical supplements are plant parts such as bark,
leaves, stems, roots, flowers, fruits, seeds and berries or
their extracts that are sold as pills, capsules or extracts
[3]. EBS refer specifically to botanical supplements with
phytoestrogenic components that may have weak estro-
genic properties, directly alter estrogen levels, or func-
tion directly on receptors in different organs as either
pro- or anti-estrogens [4]. EBS effects may differ
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nents within different plant source [5].
High estrogen levels are well-documented risk factors
for breast cancer [6-8] and anti-estrogenic therapy is a
mainstay of adjuvant treatment for breast cancer [9].
Studies of the EBS impact on endogenous estrogen
levels are mixed, showing increased [10], reduced [4], or
no association with circulating levels of estrogen [11,12].
We previously showed that, among postmenopausal
breast cancer survivors participating in the Health, Eat-
ing, Activity, and Lifestyle (HEAL) Study, EBS users had
lower estrone, estradiol and free estradiol levels than
non-EBS users [13].
Previous epidemiologic studies among breast cancer
survivors have examined the associations of CAM or
botanical supplements with HRQOL and hormone-
related symptoms showing that use was associated with
poorer mental health function [14-17], poorer physical
health function [17,18], and hormone-related symptoms
listed by the National Surgical Adjuvant Breast and
Bowel Project Breast Cancer Prevention Trial [14,19].
However, none of these studies specifically focused on
EBS use.
Here, we examine a new hypothesis to determine
whether EBS use (overall, by number of EBS types, or
by specific type used) is associated with HRQOL, fati-
gue, or 15 hormone-related symptoms among breast
cancer survivors who had survived an average of 30
months after their first primary in situ or invasive breast
cancer diagnosis.
Methods
Study population
Women participating in the HEAL Study, a multicenter,
multiethnic, prospective study of 1, 183 women diag-
nosed with first primary in situ or invasive breast cancer
between 1994 and 1999, provided the data for this ana-
lysis [20,21]. Breast cancer survivors were recruited
within 12 months (mean = 6.1 months) following their
breast cancer diagnosis through the Surveillance Epide-
miology and End Results (SEER) registries in New Mex-
ico (n = 615), Western Washington (n = 202), and Los
Angeles County (n = 366).
Of 1, 183 women who completed the baseline survey,
944 (80%) participated in a second assessment approxi-
mately 30 months (mean = 30.4 months) after diagnosis.
Of the non-participants, 44 were deceased, 104 refused
to participate, 55 could not be located, 17 could not be
contacted, and 19 were too ill.
Of the original 1, 183 women, 858 (73%) completed a
third assessment approximately 40 months (mean = 40.6
months) after diagnosis. Of the non-participants, 75 were
deceased, 140 refused to participate, 49 could not be
located, 50 could not be contacted, and 11 were too ill.
Among 829 women who completed all three surveys,
we excluded 41 women who had subsequent recur-
rences or new primaries before their 30-month assess-
ment, because these subsequent events and
corresponding treatments might influence both EBS use
and multiple health-related outcomes of interest. This
yielded a preliminary analytic sample of 788 women.
All participants provided informed consent before
each survey. The Institutional Review Boards at partici-
pating centers approved study protocols, in accordance
with assurances filed with and approved by the United
States Department of Health and Human Services.
Data collection
Diagnosis date and stage of breast cancer were based on
SEER data. Treatment data (surgery, radiation therapy,
and chemotherapy) were abstracted from medical
records or, when unavailable, from SEER data.
Baseline in-person interviews in New Mexico and Los
Angeles and self-administered questionnaires in
Washington provided data on education, race/ethnicity,
birth date, and height (measured in clinics in Washing-
ton and New Mexico and self-reported in Los Angeles).
Participants were asked about EBS use in the 30-
month assessment: ‘’S i n c ey o u rc a n c e rd i a g n o s i sh a v e
you taken any herbal or alternative remedies?’’ Partici-
pants who answered yes were given a list of 34 com-
monly used botanical or herbal supplements and asked
to indicate which, if any, of these supplements they
used. An ‘’Other’’ category was used to collect supple-
ments that were not on the list; 94 distinct supplements
were recorded via this open-ended question.
We reviewed all botanical-type supplements for evi-
dence of estrogenicity using the Physician’s Desk Refer-
ence for Herbal Medicines (PDR-H) [22]. For some
supplements, evidence of estrogenicity was not clearly
defined; however, we considered a supplement as estro-
genic if at least one study (in vitro, animal or human)
was cited that showed estrogenic properties. For supple-
ments not found in the PDR-H, we consulted Herb-
Drug Interactions in Oncology (HDIO) [23] or the Nat-
ural Medicines Comprehensive Database (NMCD) [24].
A majority of supplements (90/128, 70%) were identified
in the PDR-H, six supplements (5%) in HDIO and the
remaining 32 supplements (25%) in the NMCD. Of the
128 botanical/herbal supplements used by HEAL partici-
pants, 19 had estrogenic properties based on our defini-
tion, which included soy supplements, ginseng, flaxseed
oil, black cohosh [Cimicifuga racemosa], yam, dong
quai, red clover, licorice, alfalfa, cat’s claw, dehydroe-
piandrosterone (DHEA), astragalus, boron, burdock
root, fo ti tieng, nettles, saw palmetto, turmeric, and a
combination supplement (containing soy, black cohosh,
licorice, and dong quai).
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on menopausal status, hormone therapy (HT) use, phy-
sical activity, tamoxifen use, and weight. Menopausal
status was determined by age, menstrual status in the
past year, HT use, number of ovaries and history of hys-
terectomy using an algorithm that assigned women into
premenopausal, postmenopausal or unclassifiable meno-
pausal status. Physical activity was measured using a
version of the Modifiable Activity Questionnaire [25]
adapted for this study; the type, duration, and frequency
of 20 activities (e.g., walking, jogging, aerobics, tennis)
during the past year were assessed. The MET intensity
of each activity was classified as light, moderate, or vig-
orous based on its rating in the Compendium of Physi-
cal Activities [26]. MET hours per week of sports
activity and recreational physical activity were combined
into a total score and categorized (0, 0.1-8.9, ≥ 9M E T
hours/week) based on prior analyses in this cohort [27].
Weight was measured in clinics in Western Washington
and New Mexico and during interviews in Los Angeles.
Body mass index (kg/m
2) was based on weight measured
at the 30-month survey and height collected at the base-
line survey.
In the 30-month survey, we inquired whether partici-
pants had been diagnosed by a physician with any of 18
chronic medical conditions (e.g., angina, arthritis, osteo-
porosis, chronic lung disease, diabetes, other cancers)
and, if yes, whether that condition limited current activ-
ities of daily living. Medical comorbidity was calculated
as the number of conditions reported as limiting current
activities of daily living. We measured diet using a 122-
item self-administered food-frequency questionnaire
(FFQ) developed and validated for the Women’s Health
Initiative [28]. Isoflavones (mg/day) from soy-containing
foods on the FFQ were estimated as the sum of dietary
genestein and dietary daidzein.
We assessed participants’ HRQOL using the Medical
Outcomes Study short form-36 (SF-36) questionnaire
during the 40-month survey [29]. This tool contains 36
items and provides a physical component summary
(PCS) scale and a mental component summary (MCS)
scale. The two SF-36 summary scales are both valid and
reliable [29-31]. These scales were scored in reference to
a normal population (the 1998 general US population,
standard form) with a transformed mean of 50, and a
standard deviation of 10 [32]. Higher scores on each
scale represent better QOL; summary scale scores above
50 indicate that QOL is above average.
We also used the Revised-Piper Fatigue Scale to assess
fatigue at the 40-month assessment [33]. This scale con-
tains 22 items, measures four dimensions of subjective
fatigue (behavioral, sensory, cognitive/mood and affec-
tive), and provides an overall total fatigue score, with
higher scores indicating a greater degree of fatigue. We
used an adapted version of the Revised-Piper Fatigue
Scale score [34] that asks survivors to rate their fatigue
over the past month rather than the past week to mini-
mize the effect of acute situational events and to
enhance our assessment of the survivor’s general state
of fatigue. The Revised-Piper Fatigue Scale score has
demonstrated acceptable internal consistency, content
validity and concurrent criterion validity with adult can-
cer survivors [35-37].
We used a modified 15-symptom version of the
National Surgical Adjuvant Breast and Bowel Project
Breast Cancer Prevention Trial checklist [19,38] to col-
lect information on hormone-related symptoms at the
40-month survey asking women to indicate how much
they were bothered by any of the problems during the
past year only. The symptoms surveyed were hot flashes,
difficulty with bladder control when laughing or crying,
difficulty with bladder control at other times such as
when coughing or sneezing, vaginal discharge, genital
itching/irritation, pain with intercourse, breast sensitiv-
ity/tenderness, weight gain, unhappy with bodily appear-
ance, forgetfulness, tendency to take naps/stay in bed,
night sweats, difficulty concentrating, easily distracted,
interrupted sleep, irritability and mood swings. Response
options for the amount bothered by the symptoms were:
“N o ta ta l l ”, “Slightly”, “Moderately”, “Quite a bit”,
“Extremely”. Women who responded “Not at all” for a
given symptom were considered not to have experienced
that symptom.
Statistical analysis
We compared EBS users with non-users using Pearson
c
2 tests to evaluate differences in the frequency distribu-
tions of categorical variables and t tests to evaluate dif-
ferences in means of continuous variables.
We treated the PCS scores, MCS scores, and total fati-
gue scores as continuous variables and also dichoto-
mized the scores (low, high). Both PCS and MCS scores
were dichotomized at the standardized mean of 50 (<
50, ≥ 50) [32], which has been used previously [39,40].
The cut point for total fatigue scores was based on prior
work in this cohort (< 4, ≥ 4) [41].
Multivariable linear regression models were fit to
examine whether overall EBS use (no, yes), number of
EBS types (none, 1 type, ≥ 2 types), or specific type of
EBS (soy supplements, ginseng, flaxseed oil, black
cohosh, yam, dong quai, red clover, licorice, alfalfa, cat’s
claw, DHEA, or other EBS) was associated with continu-
ous values of the PCS scores, MCS scores, and total fati-
gue scores. We fit multivariable unconditional logistic
regression models using dichotomous outcome mea-
sures to determine whether EBS use was associated with
high PCS (≥ 50), MCS (≥ 50), or total fatigue scores (≥
4). Odds ratios (ORs) and 95% confidence intervals
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We also fit multivariable unconditional logistic regres-
sion models, to examine whether EBS use was asso-
ciated with each hormone-related symptom (yes vs. no).
All multivariable regression models adjusted for vari-
ables that were statistically significantly different when
comparing EBS users to non-users in Table 1: educa-
tion, age at diagnosis, medicial comorbidity, MET hours
per week of sports activity and recreational physical
activity from 30-month interview, a combined variable
for menopause and HT use, and isoflavones from soy-
containing foods. In the analyses of individual types of
EBS, we adjusted for all other types of EBS used.
To use a constant sample size, we excluded 21 women
who were missing information on education (n = 1),
medical comorbidity (n = 1), MET hours per week of
sports activity and recreational physical activity from 30-
month interview (n = 3), isoflavones from soy-contain-
ing foods (n = 12), HRQOL scores (n = 1), or fatigue
scores (n = 3). The 21 women did not differ from the
remaining 767 women on age at diagnosis, breast cancer
stage, or treatment for breast cancer.
In reporting results from regression analyses, we consid-
ered a two-sided P value ≤ 0.05 as statistically significant.
We did not adjust P values for multiple comparisons as
these analyses were considered as exploratory [42]. All
analyses were performed using the SAS statistical package
(Version 9.2, SAS Institute, Cary, NC).
Results
Characteristics of EBS users and non-users
EBS was used by 39.5% of women after their breast can-
cer diagnoses, including 18.4% who used only one type
and 21.1% who used two or more EBS types. Soy sup-
plements (16.6%), ginseng (13.4%), and flaxseed oil
(13.0%) were the most commonly used EBS types.
EBS users were more educated (Pc
2 < 0.0001), younger
at diagnosis (Pt-test <0 . 0 0 0 1 ) ,m o r ep h y s i c a l l ya c t i v e( Pc
2
< 0.0001), less likely to have medical comorbidity (Pc
2 =
0.007), more likely to be premenopausal (Pc
2 = 0.01), and
more likely to consume isoflavones from soy-containing
foods (Pt-test = 0.002) than non-EBS users (Table 1).
EBS use and HRQOL
Neither overall EBS use nor number of EBS types used
was associated with continuous or dichotomous
HRQOL scores (Table 2). However, a statistically non-
significant positive association was observed between
soy supplement use and continuous PCS scores (P =
0.08). Soy supplement users had 66% greater odds (OR
= 1.66, 95% CI = 1.02-2.70) of a high (≥ 50) PCS score;
but no association was observed with MCS score. Gin-
seng use was negatively associated with the continuous
PCS score (P = 0.008); ginseng users has 32% decreased
odds of a high (≥ 50) PCS score (OR = 0.68, 95% CI =
0.40-1.15); no association was observed with MCS score.
The use of flaxseed oil was not associated with continu-
ous or dichotomous PCS score. However, the use of
flaxseed oil was statistically non-significantly positively
associated with the continuous MCS score (P = 0.06).
Flaxseed oil users had 76% greater odds (OR = 1.76,
95% CI = 1.05-2.94) of a high (≥ 50) MCS score than
non-EBS users.
EBS use and total fatigue score
Neither overall EBS use nor number of EBS types used
was associated with fatigue in the linear or logistic
regression analyses (Table 3). Ginseng use was asso-
ciated with greater fatigue measured continuously (P =
0.002) as well as in the dichotomous form (OR = 1.70,
95% CI = 1.04-2.76).
EBS use and hormone-related symptoms
Although we examined the potential associations for all
the 15 symptoms with overall EBS use, number of EBS
types, and each specific EBS, we observed no associa-
tions with overall EBS use, number of EBS types, or the
majority of specific EBS. We limited presentation of
results to four specific EBS types (ginseng, red clover,
alfalfa, and DHEA) and the 10 symptoms where we
observed at least one statistically significant association
(Table 4). Ginseng use was positively associated with
vaginal discharge, unhappiness with bodily appearance,
forgetfulness, tendency to take naps or stay in bed, and
irritability and mood swings (all ORs > 1.8 and all 95%
CIs exclude 1). Red clover users were less likely to
report weight gain, night sweats, and difficulty concen-
trating (all OR approximately 0.4 and all 95% CIs
exclude 1). Alfalfa users were less likely than non-sup-
plement users to have interrupted sleep (OR = 0.28,
95% CI = 0.12-0.68). DHEA users were less likely than
non-supplement users to have hot flashes (OR = 0.33,
95% CI = 0.14-0.82).
Discussion
In the HEAL Study, neither overall EBS use nor the
number of EBS types used was associated with HRQOL,
fatigue, or hormone-related symptoms. Use of specific
EBS types (soy supplements, ginseng, flaxseed oil, red
clover, alfalfa, and DHEA) was associated with several
outcomes of interest and we focus the discussion on
these forms of EBS.
It is postulated that associations between soy supple-
ments and breast cancer risk or progression may be in
part related to the presence of isoflavones, which bind
to estrogen receptors and activate estrogen response
genes, although the hormone-like effect is much weaker
than that of endogenous estradiol or estrone [43]. The
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depend on a woman’s endogenous estrogen levels or on
the isoflavones concentration in the EBS compound.
These compounds may function as estrogen agonists in
women with low estrogen levels [44]. Results from clini-
cal trials which have evaluated the impact of soy pro-
ducts on hot flashes are mixed; three showed no effect
in breast cancer survivors [45-47] and one showed
Table 1 Study population characteristics by estrogenic botanical supplement (EBS) use
No. non-EBS users (%) No. EBS users (%) P value
a
N = 464 N = 303
Study site 0.12
Western Washington 90 (19.4) 70 (23.1)
New Mexico 259 (55.8) 146 (48.2)
Los Angeles County 115 (24.8) 87 (28.7)
Race 0.63
Non-Hispanic white 281 (60.6) 173 (57.1)
African-American 115 (24.8) 88 (29.0)
Hispanic 53 (11.4) 33 (10.9)
Others 15 (3.2) 9 (3.0)
Education < 0.0001
≤ High school 143 (30.8) 51 (16.8)
Technical school or some college 154 (33.2) 126 (41.6)
College graduate 167 (36.0) 126 (41.6)
Mean age at diagnosis (SD
b), years 56.0 (10.6) 52.5 (8.7) < 0.0001
c
Stage at diagnosis 0.41
In situ 110 (23.7) 60 (19.8)
Localized 257 (55.4) 173 (57.1)
Regional 97 (20.9) 70 (23.1)
Breast cancer treatment 0.43
No radiation and no chemotherapy 155 (33.4) 86 (28.4)
Radiation only 171 (36.9) 116 (38.3)
Chemotherapy only 45 (9.7) 29 (9.6)
Radiation and chemotherapy 93 (20.0) 72 (23.8)
Tamoxifen use 0.24
No 248 (53.5) 175 (57.8)
Yes 216 (46.6) 128 (42.2)
Medical comorbidity 0.007
None 332 (71.6) 243 (80.2)
1 or more condition(s) 132 (28.5) 60 (19.8)
Activity level within the past year of 30-month interview from sports/recreation
(MET hours/week)
< 0.0001
0 93 (20.0) 33 (10.9)
0.1-8.9 201 (43.3) 115 (38.0)
≥ 9 170 (36.6) 155 (51.2)
Menopausal status at 30-month interview 0.01
Premenopausal 74 (16.0) 68 (22.4)
Postmenopausal
Never HT
d after diagnosis 193 (41.6) 135 (44.6)
Ever HT
d after diagnosis 172 (37.1) 80 (26.4)
Unknown 25 (5.4) 20 (6.6)
Body mass index at 30-month interview (kg/m
2) 0.13
< 25 180 (38.8) 128 (42.2)
25-29 133 (28.7) 97 (32.0)
≥ 30 151 (32.5) 78 (25.7)
Mean isoflavones from soy-containing foods (SD
b), mg/day 1.9 (9.4) 4.0 (9.9) 0.002
c
aP-value ascertained from Pearson c
2 test, except where otherwise noted.
bSD, standard deviation.
cP-value from t test.
dHT, hormone therapy.
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Page 5 of 11Table 2 The association between estrogenic botanical supplement (EBS) use and health-related quality of life (HRQOL)
score
Association with continuous HRQOL score Association with better HRQOL (≥ 50)
No. Adjusted regression coefficient
(standard error)
P
value
No. with low score
<5 0
No. with high score
≥ 50
Adjusted OR
(95% CI)
Association with physical component summary (PCS)
Ever used EBS after
diagnosis
a
No 464 228 236 1.00
Yes 303 -1.27 (0.67) 0.06 142 161 0.84 (0.60-1.18)
By number of EBS used
a
1 141 -1.56 (0.86) 0.07 66 75 0.83 (0.54-1.28)
≥ 2 162 -0.99 (0.84) 0.24 76 86 0.85 (0.56-1.28)
By type of EBS used
a, b
Soy supplements 127 1.63 (0.93) 0.08 52 75 1.66 (1.02-2.70)
Ginseng 103 -2.77 (1.04) 0.008 55 48 0.68 (0.40-1.15)
Flaxseed oil 100 0.41 (1.07) 0.70 41 59 1.20 (0.68-2.09)
Black cohosh 68 -0.70 (1.31) 0.59 35 33 0.66 (0.35-1.27)
Yam 47 1.13 (1.51) 0.45 19 28 1.52 (0.70-3.27)
Dong quai 39 -1.17 (1.65) 0.48 21 18 0.70 (0.31-1.61)
Red clover 38 -1.40 (1.70) 0.41 22 16 0.61 (0.26-1.41)
Licorice 37 1.37 (1.62) 0.40 17 20 1.50 (0.64-3.47)
Alfalfa 31 -0.86 (1.76) 0.62 19 12 0.65 (0.26-1.60)
Cat’s claw 24 -2.38 (2.00) 0.23 13 11 0.80 (0.28-2.28)
DHEA 24 -1.65 (1.85) 0.37 16 8 0.40 (0.15-1.07)
Other EBS 34 1.26 (1.67) 0.45 16 18 1.17 (0.50-2.76)
Association with mental component summary (MCS)
Ever used EBS after
diagnosis
a
No 464 200 264 1.00
Yes 303 0.57 (0.80) 0.48 122 181 1.16 (0.85-1.57)
By number of EBS used
a
1 141 0.80 (1.02) 0.43 58 83 1.09 (0.74-1.61)
≥ 2 162 0.35 (1.00) 0.73 64 98 1.23 (0.84-1.79)
By type of EBS used
a, b
Soy supplements 127 1.06 (1.11) 0.34 44 83 1.42 (0.92-2.20)
Ginseng 103 -0.80 (1.24) 0.52 44 59 0.88 (0.55-1.42)
Flaxseed oil 100 2.39 (1.28) 0.06 33 67 1.76 (1.05-2.94)
Black cohosh 68 -0.50 (1.57) 0.75 28 40 0.94 (0.52-1.73)
Yam 47 -0.36 (1.81) 0.84 18 29 1.14 (0.56-2.31)
Dong quai 39 1.28 (1.97) 0.52 16 23 0.98 (0.46-2.11)
Red clover 38 0.75 (2.04) 0.71 14 24 1.15 (0.51-2.57)
Licorice 37 -1.09 (1.95) 0.57 16 21 0.79 (0.37-1.67)
Alfalfa 31 -0.11 (2.10) 0.96 13 18 0.89 (0.40-2.00)
Cat’s claw 24 -3.07 (2.40) 0.20 12 12 0.52 (0.21-1.30)
DHEA 24 1.49 (2.22) 0.50 10 14 0.93 (0.40-2.21)
Other EBS 34 0.19 (2.00) 0.93 12 22 1.25 (0.57-2.75)
aAdjusted for education, age at diagnosis, medical comorbidity, activity level within the past year of 30-month interview, a combined variable for menopause and
hormone therapy, isoflavones from soy-containing foods.
bAdditionally, all types mutually adjusted.
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cing ≥ 5 hot flushes per day [48]. One randomized con-
trolled trial observed that the incidence and severity of
hot flashes were reduced two weeks after treatment with
oral soy isoflavone extract, with no immediate reduc-
tions observed in the placebo group; the group differ-
ences achieved statistical significance at 6 weeks (P =
0.03), but decreased by 12 weeks (P = 0.08) [48]. Soy
supplement use in the HEAL Study participants was
associated with a better PCS score, but not with other
outcomes examined. Our results suggest, on the whole,
that soy supplements are unlikely to be detrimental to
breast cancer survivors’ HRQOL, fatigue, or hormone-
related symptoms.
Ginsenosides (Rh1, Rb1, and Rg1) from ginseng have
estrogen-like characteristics [49,50] and hence ginseng
might ease menopausal symptoms. Ginseng did not
influence hot flashes in a randomized, double blind, pla-
cebo-controlled study of ginseng in women reporting
high frequency of hot flashes [51]. An observational
study conducted in 2-5 years Chinese breast cancer sur-
vivors reported that ginseng use after cancer diagnosis,
particularly current use, was positively associated with
higher HRQOL scores in the psychological and social
well-being domains, but was not associated with scores
in the physical domain [52]. The findings from China
may not translate to US populations because the major
type of ginseng used could be different. An epidemiolo-
gic study conducted in US breast cancer survivors who
were, on average, 6.5 years post diagnosis reported that
ginseng users had lower SF-36 MCS scores [16]. We
observed that ginseng use was associated with a lower
PCS score, a higher fatigue score, and several hormone-
related symptoms. Although these associations with dif-
ferent symptoms are consistent with previous studies
outlining the adverse effects of ginseng [53-55], we can-
not exclude the possibility that the symptoms experi-
enced by women who took ginseng motivated their
ginseng use.
Flaxseed oil is derived from the seeds of the flax plant
that contain phytoestrogens and alpha-linolenic acid
[56,57]. Colonic microflora convert phytoestrogens to
enterolactone and enterodiol, both of which have estro-
genic and antiestrogenic properties [58]. Alpha-linolenic
acid had growth-inhibitory and proapoptotic effects on
estrogen-positive breast cancer cells [59] and decreased
the incidence, number, and growth of tumors in rats
[60,61]. In human studies, flaxseed stabilized mood,
Table 3 The association between estrogenic botanical supplement (EBS) use and total fatigue score
Association with continuous total fatigue score Association with severe fatigue (≥ 4)
No. Adjusted regression coefficient (standard
error)
P
value
No. with PFS <
4
No. with PFS ≥
4
Adjusted OR (95%
CI)
Ever used EBS after
diagnosis
a
No 464 280 184 1.00
Yes 303 0.13 (0.17) 0.44 179 124 1.06 (0.78-1.45)
By number of EBS used
a
1 141 0.11 (0.21) 0.59 86 55 0.98 (0.66-1.46)
≥ 2 162 0.14 (0.21) 0.50 93 69 1.14 (0.78-1.69)
By type of EBS used
a, b
Soy supplements 127 0.07 (0.23) 0.75 75 52 1.16 (0.74-1.80)
Ginseng 103 0.81 (0.26) 0.002 54 49 1.70 (1.04-2.76)
Flaxseed oil 100 -0.22 (0.26) 0.40 66 34 0.66 (0.39-1.12)
Black cohosh 68 -0.17 (0.32) 0.60 43 25 0.78 (0.41-1.46)
Yam 47 -0.003 (0.37) 0.99 30 17 0.94 (0.45-1.96)
Dong quai 39 -0.25 (0.40) 0.53 24 15 0.83 (0.38-1.81)
Red clover 38 -0.60 (0.42) 0.15 26 12 0.52 (0.22-1.21)
Licorice 37 0.07 (0.40) 0.85 21 16 1.41 (0.65-3.06)
Alfalfa 31 -0.39 (0.43) 0.36 21 10 0.72 (0.30-1.71)
Cat’s claw 24 0.79 (0.49) 0.11 12 12 2.03 (0.76-5.42)
DHEA 24 0.27 (0.45) 0.55 11 13 1.96 (0.82-4.70)
Other EBS 34 -0.57 (0.41) 0.16 22 12 0.79 (0.35-1.77)
aAdjusted for education, age at diagnosis, medical comorbidity, activity level within the past year of 30-month interview, a combined variable for menopause and
hormone therapy, isoflavones from soy-containing foods.
bAdditionally, all types mutually adjusted.
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Page 7 of 11improved depression symptoms [62], and reduced blood
pressure during mental stress induced by frustrating
cognitive tasks [63]. Our results are consistent with
these findings as flaxseed oil was associated with higher
MCS scores.
Red clover is another source of isoflavones, and had
some efficacy in reducing hot flashes, but did not influ-
ence quality of life, in a 12-week randomized clinical
trial [64]. In the HEAL Study, red clover use was asso-
ciated with neither HRQOL nor hot flashes. However,
red clover users were less likely to report three symp-
toms (weight gain, night sweats, and difficulty concen-
trating) than non-EBS users. Although these results
support an association of red clover with fewer meno-
pausal symptoms, it is important to note that we had
only 38 users.
Alfalfa also contains phytoestrogens and has weak
estrogenic effects [65,66]. In animal studies, alfalfa was
associated with antioxidant activity [67] and protected
against atherosclerotic lesions [68]. A small Italian study
of women experiencing hot flashes and night sweats
found that use of alfalfa and sage extracts for three
months completely alleviated symptoms in 20 of 30
women studied [69]. In the HEAL Study, alfalfa users
had a substantial but non-statistically-significant lower
risk for hot flashes and were less likely to report
Table 4 Adjusted
a OR (95% CI) for the association between estrogenic botanical supplement use and hormone-related
symptoms during last years of 30-month survey
Ginseng Red Clover Alfalfa DHEA
No Yes Adjusted
a OR
(95% CI)
No Yes Adjusted
a OR
(95% CI)
No Yes Adjusted
a OR
(95% CI)
No Yes Adjusted
a OR
(95% CI)
Hot flashes
No 179 19 1.00 191 7 1.00 187 11 1.00 187 11 1.00
Yes 485 84 1.41 (0.76-2.63) 538 31 0.99 (0.34-2.85) 549 20 0.43 (0.17-1.08) 556 13 0.33 (0.14-0.82)
Vaginal discharge
No 427 53 1.00 457 23 1.00 460 20 1.00 466 14 1.00
Yes 237 50 1.81 (1.12-2.93) 272 15 0.92 (0.42-2.05) 276 11 0.94 (0.41-2.20) 277 10 1.15 (0.48-2.73)
Weight gain
No 234 37 1.00 253 18 1.00 257 14 1.00 262 9 1.00
Yes 430 66 0.94 (0.57-1.55) 476 20 0.41 (0.19-0.91) 479 17 0.76 (0.33-1.76) 481 15 0.88 (0.36-2.11)
Unhappy with bodily
appearance
No 221 17 1.00 225 13 1.00 226 12 1.00 230 8 1.00
Yes 443 86 2.58 (1.38-4.81) 504 25 0.49 (0.21-1.17) 510 19 0.67 (0.28-1.60) 513 16 0.76 (0.30-1.93)
Forgetfulness
No 147 13 1.00 153 7 1.00 154 6 1.00 156 4 1.00
Yes 517 90 2.19 (1.11-4.33) 576 31 1.09 (0.40-2.98) 582 25 1.09 (0.39-3.02) 587 20 1.38 (0.43-4.42)
Tendency to take naps,
stay in bed
No 326 39 1.00 346 19 1.00 352 13 1.00 357 8 1.00
Yes 338 64 2.24 (1.35-3.72) 383 19 1.20 (0.54-2.70) 384 18 1.37 (0.59-3.18) 386 16 1.96 (0.79-4.87)
Night sweats
No 272 31 1.00 285 18 1.00 288 15 1.00 293 10 1.00
Yes 392 72 1.42 (0.84-2.39) 444 20 0.40 (0.18-0.90) 448 16 0.66 (0.29-1.53) 450 14 0.82 (0.34-1.97)
Difficulty concentrating
No 268 34 1.00 282 20 1.00 292 10 1.00 293 9 1.00
Yes 396 69 1.51 (0.91-2.50) 447 18 0.41 (0.18-0.90) 444 21 1.84 (0.77-4.41) 450 15 1.17 (0.48-2.84)
Interrupted sleeping
No 146 18 1.00 154 10 1.00 151 13 1.00 157 7 1.00
Yes 518 85 1.49 (0.80-2.80) 575 28 0.67 (0.26-1.77) 585 18 0.28 (0.12-0.68) 586 17 0.54 (0.21-1.39)
Irritability or mood
swings
b
No 270 24 1.00 283 11 1.00 281 13 1.00 282 12 1.00
Yes 393 79 2.19 (1.26-3.82) 445 27 1.20 (0.51-2.87) 454 18 0.79 (0.34-1.86) 460 12 0.59 (0.24-1.45)
aAdjusted for education, age at diagnosis, medical comorbidity, activity level within the past year of 30-month interview, a combined variable for menopause and
hormone therapy, isoflavones from soy-containing foods. In addition, soy supplement, ginseng, flaxseed oil, black cohosh, yam, dong quai, red clover, licorice,
alfalfa, DHEA, cat’s claw, and other EBS use mutually adjusted.
bExcluded one woman with missing information of irritability or mood swings.
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Page 8 of 11interrupted sleep than non-EBS users. These results
based on 31 alfalfa users provide some evidence that
alfalfa may reduce menopausal symptoms.
DHEA is an endogenous steroid produced and
secreted by the adrenal gland. Its sulfated form is con-
verted into androgens and estrogens by specific steroi-
dogenic enzymes. Blood DHEA levels begin to
decrease around age 30, and by menopause are
decreased 60%, on average [70]. It is reasonable to
speculate that DHEA supplements may alleviate the
symptoms caused by estrogen deficiency. A study that
administered 50 mg of DHEA to 22 women found hot
flash scores decreased 50% from baseline to week 5 of
treatment [71]. In the HEAL Study, DHEA users had
lower odds of hot flashes than non-EBS users. Our
findings, based on 24 users, support that DHEA use
m a yr e d u c eh o tf l a s h e s .
This study has several important limitations. First,
the analysis relied on self-reported EBS use. Although
our HRQOL and symptom data were collected, on
average, 10 months after the information on EBS use
that was collected, it is possible that the lower
HRQOL or the symptoms experienced by women who
took EBS were what motivated EBS use. This might
bias our results towards the null value, underestimate
the associations of EBS use with better health-related
outcomes, or yield a false association of EBS use with
poorer HRQOL or severe fatigue or other symptoms.
S e c o n d ,w ew e r eu n a b l et or u l eo u tt h ep o s s i b i l i t yt h a t
some women might have changed their number or
type of EBS they used, or non-EBS-users may have
become users during an average of 10 month interval
between our two surveys. If these events occurred,
t h e yw o u l dh a v eb i a s e do u rr e s u l t st o w a r dt h en u l l ,
limiting our ability to detect associations with EBS
use. Third, we did not collect some important infor-
mation regarding EBS use such as when EBS use was
initiated, duration or frequency of use, dosage level of
supplements taken, or reasons for use. Furthermore,
as this study is exploratory, we did not adjust for mul-
tiple comparisons. Clearly limitations restrict interpre-
tation of observed associations. The results do provide
preliminary information for future epidemiologic stu-
dies or clinical trials and add to the sparse literature
on the association of EBS use with health-related
outcomes.
We believe that this is the first epidemiologic analysis
examining the potential association of overall EBS use,
number of EBS types, and eleven commonly used types
of EBS with multiple health-related outcomes. EBS use
among breast cancer survivors is common, and data
showing the efficacy of these agents (or lack thereof) on
symptoms and HRQOL would be useful to survivors
and their healthcare providers.
Conclusions
Our results indicate the importance of assessing specific
types of EBS separately in future efficacy studies since
they may have distinct associations with health-related
outcomes. The roles of soy supplements, flaxseed oil,
red clover, alfalfa, and DHEA, in the improvement of
HRQOL or alleviation of fatigue or hormone-related
symptoms among breast cancer survivors merit further
exploration.
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